Research ProgramsNew IMP ProductsOur main area of research is on new applications of Immutep's soluble recombinant LAG-3 proteins (technology "ImmuFact®"), LAG-3 fusion proteins (technology "ImmuCcine®") and LAG-3-specific chimeric monoclonal antibodies (technology "ImmuTune®"). © 2002 Immutep, S.A.
|
Press Release
01/2011 - Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
Immutep S.A. announced today the execution of a licence agreement ...
09/2010 - Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer. 
Clinical research paper describes IMP321’s potency in achieving ...
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial 
Immutep S.A. announced today that the final results from its Phase ...
01/2010 - Interview Frederic Triebel with PharmaTelevision 01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer 
Immutep S.A. announced today the final results from its Phase I/II ...
|
|
